Anthropic is setting up a biology lab where Claude guides robots through drug experiments
Anthropic is building a San Francisco biology lab where Claude directs robots in physical drug experiments.
Anthropic is building a San Francisco-area biology laboratory so Claude can direct robots through physical drug-discovery experiments rather than simulations alone. The company has released Claude Science, a researcher workspace, and a Model Hardware Standard for controlling lab equipment, while saying human oversight remains required. In April it acquired Coefficient Bio for about $400 million and added Novartis CEO Vas Narasimhan to its board. Anthropic says it will not run its own clinical trials and highlights multi-target antibody design for diseases considered undruggable.
- Anthropic's San Francisco lab will let Claude direct robots in physical drug experiments.
- Human oversight remains required, and Anthropic will not run its own clinical trials.
- Anthropic acquired Coefficient Bio for about $400 million in April.
- Novartis CEO Vas Narasimhan joined Anthropic's board.
- Released tools include Claude Science and a Model Hardware Standard for lab equipment.
- Vendors
- Anthropic
- Organizations
- AnthropicCoefficient BioNovartis
- Countries
- United States
- AI models
- Claude
From the original article
1 min read at the-decoder.com
Anthropic is building its own biology lab to push AI-driven drug development beyond computer simulations. The article Anthropic is setting up a biology lab where Claude guides robots through drug experiments appeared first on The Decoder.
By Manuel Uth · the-decoder.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.